Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scios educates healthcare providers about Natrecor
The intent of the initiative is to educate healthcare providers regarding those patients who should receive Natrecor and those for whom Scios does not recommend the use of
The intent of the initiative is to educate healthcare providers regarding those patients who should receive Natrecor and those for whom Scios does not recommend the use of
The drug will now be promoted solely by Salix Pharmaceuticals, whilst Altana concentrates its efforts in the field of respiratory therapeutics. Mr George Cole, president, Altana Pharma US
The FDA previously granted fast track status to the overall Ancrod development program for acute ischemic stroke and now has additionally confirmed fast track status for this clinical
The phase I trial is administering AL-208 to 48 healthy adults randomized into six dose groups to evaluate safety, tolerability and pharmacokinetics. Allon expects that the study will
The primary objective of the phase II trial is to determine the efficacy of the investigational agent in terms of tumor response rate in patients with advanced bronchioloalveolar
This breakthrough could dramatically speed up the discovery of improved treatments for conditions such as diabetes, Alzheimer’s disease, Parkinson’s disease, stroke, and spinal cord injury. In laboratory experiments,
In 1999, Fibrillex received US orphan drug designation, which will give the product seven years of market exclusivity upon FDA approval. Neurochem plans to complete the submission of
The drug has previously been studied by Oxis International in an indication to treat ulcerative colitis. Because phase I safety studies were performed by Oxis during these trials,
Acute coronary syndrome (ACS) occurs when an atherosclerotic plaque ruptures in a coronary artery, which triggers the coagulation cascade resulting in the formation of a blood clot. The
The study was conducted in order to address concerns raised by the FDA regarding the safety and efficacy of the drug. In a written response to the company’s